Published online before print February 12, 2004, doi: 10.1161/01.ATV.0000121573.29550.1a
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
In-Depth Haplotype Analysis of ABCA1 Gene Polymorphisms in Relation to Plasma ApoA1 Levels and Myocardial Infarction
From INSERM U525 (D.-A.T., V.N., O.P., L.T., F.C.), Paris, France; Functional Genomic (S.R., I.A., S.S., M.R., N.D., S.M., P.D., J.-F.D.), Aventis-SA, Evry and Vitry s/Seine, France; Queen’s University Belfast (F.K., A.E.), Northern Ireland, United Kingdom; and the Monica Project (C.M.), Glasgow Royal Infirmary, Scotland, United Kingdom.
Correspondence to D. A. Tregouet, INSERM U525, Faculté de Médecine de la Pitié-Salpétrière, 91 boulevard de l’Hopital, 75364 Paris, France. E-mail david.tregouet{at}chups.jussieu.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— By regulating the cellular cholesterol efflux from peripheral cells to high-density lipoprotein, the ABCA1 protein is suspected to play a key role in lipid homeostasis and atherosclerosis. Twenty-six polymorphisms of the ABCA1 gene were genotyped and tested for association with plasma levels of ApoA1 and myocardial infarction (MI) in the ECTIM study.
Methods and Results— In addition to single-locus analysis, a systematic exploration of all possible haplotype effects was performed, with this exploration being performed on a minimal set of "tag" polymorphisms that define the haplotype structure of the gene. Two polymorphisms were associated with plasma levels of ApoA1, 1 in the promoter (C-564T) and 1 in the coding (R1587K) regions, whereas only 1 polymorphism (R219K) was associated with the risk of MI. However, no haplotype effect was detected on ApoA1 variability or on the risk of MI.
Conclusion— ABCA1 gene polymorphisms but not haplotypes are involved in the variability of plasma ApoA1 and the susceptibility to coronary artery disease.
Key Words: ABC transporters • haplotypes • atherosclerosis • coronary artery disease
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Low levels of plasma high-density lipoprotein cholesterol (HDL-C) are associated with an increased risk of atherosclerotic complications.1–3 A few environmental factors are known to affect HDL-C metabolism and plasma levels, such as physical activity,4,5 alcohol consumption,6 and cigarette smoking.7,8 The known influence of these environmental factors on the risk of coronary heart disease may be partly mediated by their effect on HDL-C metabolism. However, polymorphisms in the cholesterol ester transfer protein,9,10 lipoprotein lipase,11,12 apolipoprotein (Apo) A-I,13 and scavenger receptor class B type I 14 genes have been shown, to some extent at least, to affect plasma HDL-C levels. However, their contribution to clinical endpoints is, at most, very weak.
Because of the recognition of its implication in Tangier disease,15 a rare form of genetic HDL deficiency, the ATP-binding cassette transporter 1 (ABCA1) has been investigated extensively and is now recognized as a key player in the reverse transport of cholesterol from peripheral cells to the liver and other organs.16–19 ABCA1 is a member of the ABC membrane transporters family, which comprises proteins translocating a wide variety of substrates across cellular membranes.20 It has been suggested that ABCA1 participates in the efflux of free cholesterol from peripheral cells, including macrophage-derived foam cells, and contributes to the formation of mature HDL by facilitating the lipidation of circulating nascent ApoA-I particles with free cholesterol at the plasma membrane.16,21,22 Functional deficiency of ABCA1 could therefore induce an atherogenic decrease in HDL-C levels, incriminating the ABCA1 gene as a candidate for atherosclerotic complications. This hypothesis has been supported by recent studies showing that in addition to rare mutations,23–25 common polymorphisms in the ABCA1 gene also affect HDL-C concentrations and could be of clinical importance.23,25–29 These results were not, however, entirely consistent; in particular, a dissociation was shown between the effect of these polymorphisms on HDL-C and other circulating lipid variables.23,26 Although ABCA1 polymorphisms may have only a weak effect on commonly measured lipid parameters such as HDL-C, they may have a stronger impact on more specific phenotypes such as apolipoproteins.
The aim of this study was to investigate whether ABCA1 gene polymorphisms could be associated with the risk of myocardial infarction (MI) and the variability of ApoA1 levels. For this purpose, a molecular screening of the ABCA1 gene was first performed to identify all common polymorphisms in the coding and promoter regions of the gene in individuals of European origin. Identified polymorphisms were further genotyped in the ECTIM Study,30 a case-control study of MI, and tested for association with plasma ApoA-I levels and with MI. Association analysis was performed by use of our recently proposed haplotype-based analysis method31 in order to better characterize the contribution of ABCA1 gene haplotypes to ApoA1 variability and the risk of MI.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Screening of the ABCA1 Gene for Detection of Polymorphisms
The molecular screening of the ABCA1 gene was performed on genomic DNA obtained from 32 individuals of European origin. The entire coding sequence and the promoter region of the ABCA1 gene were analyzed as well as were intronic sequences flanking exons. Primary polymerase chain reaction (PCR) amplification primers were designed using Prime Software (cgc package) and specific amplification was achieved using the selected PCR primers. Sequencing reactions were performed in 10 µL, using 2 µL of purified PCR product, 10 µmol/L amplification primer forward or reverse from PCR reaction (0.5 µL), and 1.5 µL of BigDye terminator kit (Applied Biosystems). All reactions were cleaned using G50 Sephadex columns as recommended by the supplier (Amersham Pharmacia Biotech). The samples were processed using an ABI 3700 as recommended by the supplier (Applied Biosystems). The traces were analyzed with the package Phred Phrap Polyphred and Consed (Washington University). The polymorphisms were then blasted against the protein to identify the amino acid changes.
Genotyping of the ABCA1 Gene Polymorphisms
All genotyped single nucleotide polymorphisms (SNPs) were analyzed in different sets of 2, 3, or 4 SNPs. For each set of SNPs, primary PCR amplification primers were designed using Prime Software (cgc package). The single base extension (SBE) oligonucleotides were chosen 20 bp upstream or downstream of the polymorphic site so that the 3' end terminates 1 base before the polymorphic site. A thymine (T) tail was 5' added to the second, third, and fourth SBE primers to allow separation of each marker according to its length. The T-tails were, respectively, 0T, 6T, 12T, and 18T. Specific amplification of the genomic regions containing the SNPs was achieved using the PCR primers. After SBE reaction, a size-standard labeled on a fifth dye (Applied Biosystems) was added to 3 µL of the SBE reaction in a final volume of 15 µL. The samples were processed using an ABI 3700 as recommended by the supplier (Applied Biosystems). The samples were analyzed with Genscan for size-standard definition and allele pics recognition. The pics information was exported to a matrix file (Genotyper software, Applied Biosystems) in which the markers data were stored. Alleles were determined from the presence of 1 or 2 pics in two different colors.
Study Population
All SNPs identified in the promoter and translated coding regions were then genotyped in the ECTIM study. The ECTIM study design has been described elsewhere.30 The initial study population has been extended by the recruitment of further population samples from the United Kingdom in Belfast and Glasgow.32 The results reported here are based on samples of subjects from populations covered by WHO MONICA Project registers in the United Kingdom: Belfast (Northern Ireland) and Glasgow (Scotland). Patients (33% females) aged 25 to 64 (for males) and 25 to 69 years (for females) (mean age±SD: 56.3±8.1 years) were recruited between 3 and 9 months (2 years for females in Belfast) after the index MI. Controls of the same sex and comparable age were recruited from the lists of general practitioners in the same areas in the United Kingdom (mean age±SD: 57.3±8.0 years). In the present analysis, DNA was available for 800 cases and 776 controls. However, haplotype analyses were performed on smaller numbers of individuals because of missing genotypic data at polymorphisms. Each participant provided written informed consent. The methodology used to assess plasma ApoA1 levels has been described previously.30
Statistical Analysis
Allele frequencies were estimated by gene counting. Departure from Hardy-Weinberg equilibrium was tested in each center using a 
2 with 1 degree of freedom (df), and pair-wise linkage disequilibrium (LD) was estimated using a log-linear model analysis.33 The extent of LD was expressed as D', which is the ratio of the unstandardized coefficient to its minimal/maximal value.34
For case-control comparisons, controls with coronary heart disease were excluded. For each polymorphism, allelic odds ratios (ORs) were calculated by a logistic regression adjusted for age, sex, and center. Association between plasma ApoA1 levels with each ABCA1 gene polymorphisms was performed by classical linear regression analysis assuming additivity of the allele effects after adjusting for age, sex, center, and case/control status. Heterogeneity of effects between cases and controls was tested by introducing the corresponding interaction term.
To better-characterize the contribution of ABCA1 gene polymorphisms on ApoAI level variability and on the risk of MI, haplotype analyses were performed by use of our maximum likelihood method for haplotype–phenotype association analysis.31,35 Haplotype analysis was performed using a 2-step strategy. Haplotype frequencies derived from all the studied polymorphisms were first estimated independently of any phenotype. Based on the inferred haplotypic structure, we determined computationally, among the 2K-1 possible combinations of 1 to K polymorphisms, a minimal set of polymorphisms that was sufficient for characterizing all haplotypes with a frequency >0.01. For this purpose, we developed a program similar to that recently described.36 The association between ABCA1 gene haplotypes and any phenotype was then investigated by use of these polymorphisms. Using this reduced set of "tag" polymorphisms had the advantage of decreasing the number of discarded individuals because of missing genotype data and of facilitating the interpretation of the results (see later) without losing any information on the haplotypic structure of the gene.
To reduce the haplotype dimension and to select the most informative and parsimonious haplotype configuration in terms of prediction of the phenotypic variability, we applied our maximum likelihood model to all possible 1 to k-loci combinations of polymorphisms that could be derived from the set of k "tag" polymorphisms. For each model, including the model with no polymorphism, an information criteria, AIC,37 was calculated. All AIC values were rescaled by subtracting the minimum AIC value obtained over all models explored. Following a rule derived by extensive Monte Carlo simulation,38 all models with a rescaled AIC 
2 could be considered as "equivalent" to the model leading to the minAIC. Among those, the most parsimonious one corresponding to the minimal haplotype configuration was retained. Note that this "best" model could be the one without any polymorphism.
Haplotype analyses were adjusted for sex, age, center, and ApoAI level (for case-control comparison) or case-control status (for ApoAI levels).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Identification of ABCA1 Gene Polymorphisms
The present report focused on the analysis of 16 polymorphisms located in the promoter region and 10 polymorphisms in the translated coding region of the gene.
Characteristics of the identified ABCA1 gene polymorphisms are reported in Table 1. In particular, the -777rpt polymorphism was characterized by 4 different alleles depending on the size of the repeat region: 19, 23, 28, or 32 nucleotides. These will be referred to as allele 1, 2, 3, and 4, respectively. Allele 1 was carried by only 1 subject (case) who was then eliminated from analyses. Among the 10 polymorphisms in the coding region, 6 induced an amino acid change and 4 were synonymous. No deviation from Hardy-Weinberg equilibrium was observed for any polymorphism. No allele frequency difference was observed between Belfast and Glasgow for any polymorphism.
|
Detailed description of the LD pattern can be found at our web site (http://genecanvas.ecgene.net). Polymorphisms in the promoter region were strongly associated, with LD being complete for most of the pairs. Because the A-1652G, the G-1506C, and the G-407 polymorphisms were nearly completely concordant (<1% of recombinants) with the A-1814G, the -777rpt, and the G-564T polymorphisms, respectively, they were not considered for analysis. Strong LD was also present in the coding region for 1 cluster of polymorphisms (R219K, G316G, I680I, V771 M, V825I, I883 M) located in exons 8 to 17. Outside the region encompassing this set of polymorphisms, LD was weak or absent. This is likely the consequence of the large size of the hABCA1 gene sequence, which is distributed over a region of almost 150 kb. LD between the promoter and the coding polymorphisms was very weak. Therefore, haplotype analysis was performed in the promoter and the coding regions separately.
Association Analysis of ABCA1 Gene Polymorphisms With MI
To simplify the presentation, the genotype frequency distributions of all the polymorphisms investigated are not reported here but can be found at our web site. No significant heterogeneity in the association of MI with any polymorphism was observed between males and females.
Promoter Region
None of the polymorphisms was associated with MI by univariate analysis. As a consequence of the strong LD between polymorphisms, a limited number of haplotypes was inferred from the genotypic data (Table 2). Ten haplotypes with a frequency ranging from 0.01 to 0.30 accounted for >91% of all chromosomes. The haplotypic structure of the promoter could be fully characterized by a subset of 5 "tag" polymorphisms, A-1814G, A-1034I/D, T-940G, G-803A, and C-14T (Table 2). Globally, haplotype frequency distribution did not differ between patients and controls (2=13.12 with 9 df; P=0.15). Results of the full exploration of all models are available online. The most parsimonious and informative model was the one including no polymorphism, which is the model specifying no haplotype effect.
|
Coding Region
By single-locus analysis, the R219K polymorphism was associated with MI, with K219 allele being associated with a decreased risk consistently in the 2 centers (population adjusted OR=0.80 [0.68–0.94], P=0.007).
Sixteen haplotypes with a frequency >0.01 were inferred from the genotypic data of all individuals and accounted for >96% of all chromosomes (Table 3). The most frequent haplotype (
50%) was the one combining the most frequent allele at each site. The frequency of the other haplotypes ranged from 0.012 to 0.084. Because of the weak LD between polymorphisms of the coding region, a subset of 8 "tag" polymorphisms was required to characterize the inferred haplotypic structure (Table 3). After adjusting for sex, age, center, and ApoA1 levels, the whole haplotype frequency distribution did not differ between cases and controls (2=17.28 with 15 df; P=0.302). The "best" model encountered in the systematic exploration was the model with the R219K polymorphism alone, suggesting that apart from the raw effect of the R219K polymorphism, no other polymorphism was associated with the risk of MI.
|
Finally, when investigating whether this association could be modulated by potential modifiers including alcohol, body mass index, and smoking, we observed that it was mainly present in nonsmokers (OR=0.67 [0.53–0.84], P<10-3) but not in smokers (OR=0.95 [0.73–1.22], P=0.66; test for interaction P=0.05).
Association Analysis of ABCA1 Gene Polymorphisms With ApoA1 Levels
Plasma levels of ApoA1 were lower in cases than in controls (mean±SEM: 1.41±0.01 versus 1.57±0.01 (mg/mL), P<10-4) and were higher in females than in males (1.56±0.01 versus 1.42±0.01 mg/mL, P<10-4), irrespective of clinical status. Full description of the association between each ABCA1 gene polymorphism and ApoA1 levels can be found at our web site.
Promoter Region
By single-locus analysis, the C-564T polymorphism was the only polymorphism of the promoter region significantly associated with plasma ApoA1 levels. The -564T allele was associated with increased plasma ApoA1 levels (1.47 versus 1.49 versus 1.51; R2=0.5%; P=0.015, in CC, CT, and TT, respectively). The association was homogeneous in patients and controls (data not shown). The test for a global haplotypic effect was not significant (2=12.38 with 8 df, P=0.135). The "best haplotypic model" with respect to ApoA1 levels was the model including the T-940G polymorphism alone, whose association with ApoA1 levels was borderline in univariate analysis (P=0.089, data available at our web site). Note that the C-564T was not included in the subset of 5 "tag" polymorphisms, which explains why it was not selected by haplotype analysis. However, the T-940G polymorphism was in strong LD with the C-564T polymorphism. These results suggested that variation in the promoter influenced plasma ApoA1 levels, but it was not possible from haplotype analysis to clearly identify the potentially functional polymorphisms.
Coding Region
By single-locus analysis, the R1587K polymorphism was the only one in the coding region that was significantly associated with plasma levels of ApoA1. The association was homogeneous in patients and controls, with the K1587 allele being significantly associated with decreased ApoA1 levels (1.51 versus 1.47 versus 1.45; R2=0.7%; P<10-4, in RR, RK, and KK, respectively). The test for a global haplotypic effect was not significant (2=20.57 with 15 df, P=0.151). Because the most informative and parsimonious model with regard to plasma ApoA1 levels was the model including the R1587K polymorphism alone, it could be deduced from the principle of parsimony that the association between plasma ApoA1 levels and haplotype variability in the coding region was caused by only the R1587K polymorphism.
Note that similar results were observed when haplotype analyses were repeated after excluding individuals who were using lipid-lowering drugs (data available at our web site).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Much attention has been focused on the association of ABCA1 gene polymorphisms with different phenotypes including lipid variables and clinical endpoints.23,25–29,39 Several studies have consistently reported an association between the R219K polymorphism and coronary artery disease.23,26,27 This polymorphism has been shown to be associated with triglycerides23 but not with HDL-C.26,27 Inconsistent results were also observed for other ABCA1 gene polymorphisms including V825I, I883 M, and E1172D. One of the objectives of this work was to investigate the association of ABCA1 gene polymorphisms with plasma ApoA1 levels. To this end, a molecular screening of the promoter and coding regions of the ABCA1 gene was performed, which led to the identification of already known polymorphisms and new ones mainly in the promoter region. However, our molecular screening failed to identify 2 previously identified polymorphisms located in the promoter region (G-191C and C-17G).29 It cannot be excluded that our sample size of 32 healthy individuals was too small to identify these polymorphisms that have been identified in patients with coronary artery disease and have also shown to be associated with an increase of coronary events. The polymorphisms identified were then genotyped in the ECTIM study30 and tested for association with MI and ApoA1 levels. The single-locus analysis may provide misleading results if particular combinations of nucleotides on the same chromosome, ie, haplotypes, constitute the relevant genetic units with regard to the phenotypes. These haplotypes may serve as markers for unknown functional variants or may define functional units whose effects cannot be predicted from what is known of the effect of each variant. Our strategy of haplotype analysis was first to define the haplotypic variability of the ABCA1 gene by identifying "tag" polymorphisms and then to perform haplotype–phenotype association analysis by use of these "tag" polymorphisms. Because LD was very weak between the promoter and coding regions, haplotype analysis was performed separately within these 2 blocks, as we have already performed in previous work.31 However, it cannot be excluded that some functional haplotypes might be defined by some polymorphisms that are not in LD.31
Because of the strong LD within the promoter region of the ABCA1 gene, the haplotypic diversity of this region was rather low, with 5 "tag" polymorphisms (A-1814G, A-1034I/D, T-940G, G-803A, and C-14T), among the 14 polymorphisms identified, defining 11 frequent haplotypes. This set of 5 "tag" polymorphisms was not unique because the T-940G could have been replaced by a repeat polymorphism at position -777 without changing the results of the analysis (data not shown). No single-locus or haplotype effect was observed on the risk of MI. The C-564T polymorphism was marginally associated with ApoA1 levels, with the T allele being associated with increased levels. Note that the C-564T polymorphism was in strong LD with the C-14T polymorphism that was shown to be associated with HDL-C in a Chinese population.39
Unlike what was observed in the promoter region, the LD was rather weak between polymorphisms located in the coding region; most of these polymorphisms are relatively rare. Of the 10 identified polymorphisms in this region, 8 were required to characterize the 16 main haplotypes inferred. The R1587K polymorphism that was not in LD with any other polymorphism was the only one associated with plasma ApoA1 variability. The K1587 allele was associated with decreased plasma ApoA1 levels. No significant association of this polymorphism was observed with MI, although carriers of the K1587 allele (RK and KK) were at slightly decreased risk of MI (OR: 0.76; 95% CI: 0.61–0.94; P=0.013). These results are quite consistent with those of a previous study that also showed that the R1587K polymorphism was associated with HDL-C but not with coronary artery disease.23 No other polymorphism within the coding region seemed to modulate the variability of plasma ApoA1. Conversely, the R219K polymorphism was associated with MI but not with ApoA1 levels. The K219 allele was associated with a decreased risk of MI (OR: 0.80; 95% CI: 0.68–0.94; P=0.007) as previously reported.23,26,27 Interestingly, the protective effect of the K219 allele was more pronounced in nonsmokers than in smokers, as previously observed.27
ABCA1 shows limited interaction with the major HDL species isolated from plasma.18 This may explain why in our study the association between the ABCA1 polymorphisms and HDL-C was consistent but weaker than that observed between the polymorphisms and ApoA1 (data not shown).
Overall, these results in addition to those of other studies suggest an implication of ABCA1 polymorphisms in the variability of plasma ApoA1 and the susceptibility to coronary artery disease. In the presence of ApoA1, ABCA1 promotes cellular efflux of cholesterol and ABCA1 cross-links to lipid-poor ApoA1. One explanation for the observed association would be that the ABCA1 polymorphisms affect the interaction between ABCA1 and ApoA1; however, we have no experimental proof that this is the case. There are also a number of inconsistencies in the results that we are unable to explain for the moment, especially the fact that R1587K affects plasma ApoA1 but appears unrelated to MI and conversely that R219K is associated with MI but does not affect plasma ApoA1 levels. It is important to keep in mind that because the ECTIM Study was designed to recruit MI survivors within defined geographic areas, a survival bias could obviously result from the high early lethality of MI. An unbiased picture could be provided only by a prospective study in which the outcome also includes MI deaths.
Although haplotype analyses have the advantages of reducing the number of statistical tests to be performed when investigating the interaction between several polymorphisms,31 a simulation study40 has recently shown that the power for detecting moderate haplotypic effects (OR 2) was quite moderate even in large samples (N=1000). Therefore, it cannot be excluded that our analysis failed to identify haplotype effects because of a lack of power, especially if haplotype effects deviated from the assumed hypothesis of additivity.
It is remarkable that the R1587K polymorphism was not in LD with any other polymorphisms in the gene, implying that its direct identification was required to detect its effect on plasma ApoA1 levels. A general conclusion that we can draw from this observation is that in a number of instances, genetic markers may be useless and that direct identification of a "functional" polymorphism may be required. This suggests an exhaustive analysis of candidate gene polymorphisms as opposed to an analysis based on some selected markers. In addition, we must note that for a polymorphism like R1587K, haplotype analysis was useless and even blurred an association that was evident with the polymorphism alone. It is also interesting to mention that despite the large number of polymorphisms within the ABCA1 gene, no haplotypic effect was found in the present analyses unlike what has been observed for other genes.10,31
|
Acknowledgments |
|---|
Acknowledgments
We are grateful to all investigators of the ECTIM study.
Received December 10, 2003; accepted January 20, 2004.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Gordon DJ, Rifkind BM. High-density lipoprotein–the clinical implications of recent studies. N Engl J Med. 1989; 321: 1311–1316.[Medline] [Order article via Infotrieve]
2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971; 74: 1–12.
3. Krieger M. The "best" of cholesterols, the "worst" of cholesterols: a tale of two receptors. Proc Natl Acad Sci U S A. 1998; 95: 4077–4080.
4. Byberg L, Zethelius B, McKeigue PM, Lithell HO. Changes in physical activity are associated with changes in metabolic cardiovascular risk factors. Diabetologia. 2001; 44: 2134–2139.[CrossRef][Medline] [Order article via Infotrieve]
5. Marrugat J, Elosua R, Covas MI, Molina L, Rubies-Prat J. Amount and intensity of physical activity, physical fitness, and serum lipids in men. The MARATHOM Investigators. Am J Epidemiol. 1996; 143: 562–569.
6. Pownall HJ. Alcohol: lipid metabolism and cardioprotection. Curr Atheroscler Rep. 2002; 4: 107–112.[Medline] [Order article via Infotrieve]
7. Criqui MH. Epidemiology of atherosclerosis: an updated overview. Am J Cardiol. 1986; 57: 18C–23C.[CrossRef][Medline] [Order article via Infotrieve]
8. Rigotti NA, Pasternak RC. Cigarette smoking and coronary heart disease: risks and management. Cardiol Clin. 1996; 14: 51–68.[Medline] [Order article via Infotrieve]
9. Corbex M, Poirier O, Fumeron F, Betoulle D, Evans A, Ruidavets JB, Arveiler D, Luc G, Tiret L, Cambien F. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol. 2000; 19: 64–80.[CrossRef][Medline] [Order article via Infotrieve]
10. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C–>A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet. 2003; 12: 111–123.
11. Fisher RM, Humphries SE, Talmud PJ. Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis. Atherosclerosis. 1997; 135: 145–159.[CrossRef][Medline] [Order article via Infotrieve]
12. Jemaa R, Fumeron F, Poirier O, Lecerf L, Evans A, Arveiler D, Luc G, Cambou JP, Bard JM, Fruchart JC, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Temoin sur l’Infarctus du Myocarde. J Lipid Res. 1995; 36: 2141–2146.[Abstract]
13. Carmena-Ramon RF, Ordovas JM, Ascaso JF, Real J, Priego MA, Carmena R. Influence of genetic variation at the apo A-I gene locus on lipid levels and response to diet in familial hypercholesterolemia. Atherosclerosis. 1998; 139: 107–113.[CrossRef][Medline] [Order article via Infotrieve]
14. Acton S, Osgood D, Donoghue M, Corella D, Pocovi M, Cenarro A, Mozas P, Keilty J, Squazzo S, Woolf EA, Ordovas JM. Association of polymorphisms at the SR-BI gene locus with plasma lipid levels and body mass index in a white population. Arterioscler Thromb Vasc Biol. 1999; 19: 1734–1743.
15. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999; 22: 352–355.[CrossRef][Medline] [Order article via Infotrieve]
16. Kwiterovich PO, Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 2000; 86: 5L–10L.[Medline] [Order article via Infotrieve]
17. Owen JS. Role of ABC1 gene in cholesterol efflux and atheroprotection. Lancet. 1999; 354: 1402–1403.[CrossRef][Medline] [Order article via Infotrieve]
18. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest. 2002; 110: 899–904.[CrossRef][Medline] [Order article via Infotrieve]
19. Yancey PG, Bortnick AE, Kellner-Weibel G, De La Llera-Moya M, Phillips MC, Rothblat GH. Importance of Different Pathways of Cellular Cholesterol Efflux. Arterioscler Thromb Vasc Biol. 2003; 23: 712–719.
20. Jones PM, George AM. Mechanism of ABC transporters: a molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc Natl Acad Sci U S A. 2002; 99: 12639–12644.
21. Oram JF. Tangier disease and ABCA1. Biochim Biophys Acta. 2000; 1529: 321–330.[Medline] [Order article via Infotrieve]
22. Remaley AT, Rust S, Rosier M, Knapper C, Naudin L, Broccardo C, Peterson KM, Koch C, Arnould I, Prades C, Duverger N, Funke H, Assman G, Dinger M, Dean M, Chimini G, Santamarina-Fojo S, Fredrickson DS, Denefle P, Brewer HB, Jr. Human AT. P-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. Proc Natl Acad Sci U S A. 1999; 96: 12685–12690.
23. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J, Jr., Kastelein JJ, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 2001; 103: 1198–1205.
24. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJ. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet. 2002; 359: 37–42.[CrossRef][Medline] [Order article via Infotrieve]
25. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJ, Connelly PW, Harris SB, Hegele RA. Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterioscler Thromb Vasc Biol. 2000; 20: 1983–1989.
26. Brousseau ME, Bodzioch M, Schaefer EJ, Goldkamp AL, Kielar D, Probst M, Ordovas JM, Aslanidis C, Lackner KJ, Bloomfield Rubins H, Collins D, Robins SJ, Wilson PW, Schmitz G. Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis. 2001; 154: 607–611.[CrossRef][Medline] [Order article via Infotrieve]
27. Cenarro A, Artieda M, Castillo S, Mozas P, Reyes G, Tejedor D, Alonso R, Mata P, Pocovi M, Civeira F. A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. J Med Genet. 2003; 40: 163–168.
28. Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM, Jr., Marian AJ. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res. 2001; 88: 969–973.
29. Zwarts K, Clee S, Zwinderman A, Engert J, Singaraja R, Loubser O, James E, Roomp K, Hudson T, Jukema J, Kastelein J, Hayden M. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin Genet. 2002; 61: 115–125.[CrossRef][Medline] [Order article via Infotrieve]
30. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb. 1992; 12: 701–707.
31. Tregouet DA, Barbaux S, Escolano S, Tahri N, Golmard JL, Tiret L, Cambien F. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet. 2002; 11: 2015–2023.
32. Kee F, Morrison C, Evans AE, McCrum E, McMaster D, Dallongeville J, Nicaud V, Poirier O, Cambien F. Polymorphisms of the P-selectin gene and risk of myocardial infarction in men and women in the ECTIM extension study. Etude cas-temoin de l’infarctus myocarde. Heart. 2000; 84: 548–552.
33. Tiret L, Amouyel P, Rakotovao R, Cambien F, Ducimetiere P. Testing for association between disease and linked marker loci: a log-linear-model analysis. Am J Hum Genet. 1991; 48: 926–934.[Medline] [Order article via Infotrieve]
34. Nei M. Molecular Evolutionary Genetics. New York: Columbia University Press; 1987.
35. Tregouet DA, Barbaux S, Poirier O, Blankenberg S, Bickel C, Escolano S, Rupprecht HJ, Cambien F, Tiret L. SELPLG gene polymorphisms in relation to plasma SELPLG levels and coronary artery disease. Ann Hum Genet. 2003; 67: 504–511.[CrossRef][Medline] [Order article via Infotrieve]
36. Sebastiani P, Lazarus R, Weiss ST, Kunkel LM, Kohane IS, Ramoni MF. Minimal haplotype tagging. Proc Natl Acad Sci U S A. 2003; 100: 9900–9905.
37. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automated Control AC. 1974; 19: 716–723.[CrossRef]
38. Burnham KP, Anderson DR. Model selection and inference: a practical information-theoretical approach. New York: Springer-Verlag; 2002.
39. Tan JH, Low PS, Tan YS, Tong MC, Saha N, Yang H, Heng CK. ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore. Hum Genet. 2003; 113: 106–117.[Medline] [Order article via Infotrieve]
40. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet. 2004;in press.
This article has been cited by other articles:
 |
|
 |
|
  J. J. Regieli, J. W. Jukema, P. A. Doevendans, A. H. Zwinderman, J. J. Kastelein, D. E. Grobbee, and Y. van der Graaf Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1238 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Regieli, J. W. Jukema, D. E. Grobbee, J. J.P. Kastelein, J. A. Kuivenhoven, A. H. Zwinderman, Y. van der Graaf, M. L. Bots, and P. A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur. Heart J., November 2, 2008; 29(22): 2792 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamada, N. Metoki, H. Yoshida, K. Satoh, K. Kato, T. Hibino, K. Yokoi, S. Watanabe, S. Ichihara, Y. Aoyagi, et al. Genetic Factors for Ischemic and Hemorrhagic Stroke in Japanese Individuals Stroke, August 1, 2008; 39(8): 2211 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frikke-Schmidt, B. G. Nordestgaard, G. B. Jensen, R. Steffensen, and A. Tybjaerg-Hansen Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 180 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hughes, O. Agbaje, R. L. Bowen, D. L. Holliday, J. A. Shaw, S. Duffy, and J. L. Jones Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression Clin. Cancer Res., November 15, 2007; 13(22): 6673 - 6680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cambien and L. Tiret Genetics of Cardiovascular Diseases: From Single Mutations to the Whole Genome Circulation, October 9, 2007; 116(15): 1714 - 1724. [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Villarreal-Molina, C. A. Aguilar-Salinas, M. Rodriguez-Cruz, D. Riano, M. Villalobos-Comparan, R. Coral-Vazquez, M. Menjivar, P. Yescas-Gomez, M. Konigsoerg-Fainstein, S. Romero-Hidalgo, et al. The ATP-Binding Cassette Transporter A1 R230C Variant Affects HDL Cholesterol Levels and BMI in the Mexican Population: Association With Obesity and Obesity-Related Comorbidities Diabetes, July 1, 2007; 56(7): 1881 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kyriakou, D. E. Pontefract, E. Viturro, C. P. Hodgkinson, R. C. Laxton, N. Bogari, G. Cooper, M. Davies, J. Giblett, I. N.M. Day, et al. Functional polymorphism in ABCA1 influences age of symptom onset in coronary artery disease patients Hum. Mol. Genet., June 15, 2007; 16(12): 1412 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soro-Paavonen, J. Naukkarinen, M. Lee-Rueckert, H. Watanabe, E. Rantala, S. Soderlund, A. Hiukka, P. T. Kovanen, M. Jauhiainen, L. Peltonen, et al. Common ABCA1 variants, HDL levels, and cellular cholesterol efflux in subjects with familial low HDL J. Lipid Res., June 1, 2007; 48(6): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Iglseder, H. Oberkofler, T. K. Felder, K. Klein, B. Paulweber, F. Krempler, D. A. Tregouet, and W. Patsch Associations of PPARGC1A Haplotypes With Plaque Score but Not With Intima-Media Thickness of Carotid Arteries in Middle-Aged Subjects Stroke, September 1, 2006; 37(9): 2260 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Blankenberg, T. Godefroy, O. Poirier, H. J. Rupprecht, S. Barbaux, C. Bickel, V. Nicaud, R. Schnabel, F. Kee, C. Morrison, et al. Haplotypes of the Caspase-1 Gene, Plasma Caspase-1 Levels, and Cardiovascular Risk Circ. Res., July 7, 2006; 99(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Van Eck, R. R. Singaraja, D. Ye, R. B. Hildebrand, E. R. James, M. R. Hayden, and T. J.C. Van Berkel Macrophage ATP-Binding Cassette Transporter A1 Overexpression Inhibits Atherosclerotic Lesion Progression in Low-Density Lipoprotein Receptor Knockout Mice Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 929 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Pearce, D.-A. Tregouet, A. Samnegard, A. R. Morgan, C. Cox, A. Hamsten, P. Eriksson, and S. Ye Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction Circ. Res., November 11, 2005; 97(10): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Frikke-Schmidt, B. G. Nordestgaard, P. Schnohr, R. Steffensen, and A. Tybjaerg-Hansen Mutation in ABCA1 Predicted Risk of Ischemic Heart Disease in the Copenhagen City Heart Study Population J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1516 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fasano, L. Bocchi, L. Pisciotta, S. Bertolini, and S. Calandra Denaturing high-performance liquid chromatography in the detection of ABCA1 gene mutations in familial HDL deficiency J. Lipid Res., April 1, 2005; 46(4): 817 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kyriakou, C. Hodgkinson, D. E. Pontefract, S. Iyengar, W. M. Howell, Y.-k. Wong, P. Eriksson, and S. Ye Genotypic Effect of the -565C>T Polymorphism in the ABCA1 Gene Promoter on ABCA1 Expression and Severity of Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Cohen, R. S. Kiss, A. Pertsemlidis, Y. L. Marcel, R. McPherson, and H. H. Hobbs Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol Science, August 6, 2004; 305(5685): 869 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Putt, J. Palmen, V. Nicaud, D.-A. Tregouet, N. Tahri-Daizadeh, D. M. Flavell, S. E. Humphries, P. J. Talmud, and on behalf of the EARSII group Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II Hum. Mol. Genet., August 1, 2004; 13(15): 1587 - 1597. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||